Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib. Issue 15 (March 2021)

• Record Type: Journal Article
• Authors: Rahaghi, Franck; Belperio, John A; Fitzgerald, John; Gulati, Mridu; Hallowell, Robert; Highland, Kristin B; Huie, Tristan J; Kim, Hyun J; Kolb, Martin; Lasky, Joseph A; Southern, Brian D; Swigris, Jeffrey J; de Andrade, Joao A
• Is Part Of: Clinical medicine insights. Issue 15(2021)
• Publication Date: 2021-03
• Subjects: Comorbidity -- drug interactions -- interstitial lung disease -- safety -- tyrosine kinase; Cardiovascular system -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Periodicals; Blood Circulation; Respiration; Lung Diseases; Cardiovascular system -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; Periodicals; 616.1005
• DOI: 10.1177/11795484211006050
• Languages: English
• ISSNs: 1179-5484

Abstract

Purpose: Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF), which slows disease progression. Management of patients with IPF receiving nintedanib can be complicated by tolerability issues, comorbidities, and concomitant medications. We developed consensus recommendations on the management of dosing, adverse events and comorbidities in patients with IPF treated with nintedanib. Methods: A modified Delphi process using 3 questionnaires was used to survey 14 pulmonologists experienced in using nintedanib. Panelists rated their agreement with statements on a Likert scale from −5 (strongly disagree) to +5 (strongly agree). Consensus was predefined as a mean score of ⩽−2.5 or ⩾+2.5 with a standard deviation not crossing zero. Results: The panelists' recommendations were largely aligned with clinical trial data, real-world evidence, and the prescribing information, and provided additional guidance regarding minimizing gastrointestinal effects, periodic monitoring for liver dysfunction, caution with respect to concomitant administration of cytochrome P450 3A4 and P-glycoprotein 1 inhibitors and inducers and anticoagulants, and management of comorbidities. The panelists unanimously agreed that adverse event management should be individualized, based on careful consideration of the risks and benefits of each possible intervention and discussion with the patient. Conclusions: These consensus recommendations provide additional guidance on the appropriate management of IPF with nintedanib, for use alongside evidence-based literature and the prescribing information.